BioSpace News Archive

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease despite two or more prior lines of therapy.

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021.